Showing 2541-2550 of 5646 results for "".
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- Scottish Medicines Consortium Accepts Iluvien for Prevention of Relapse in Recurrent Noninfectious Uveitishttps://modernod.com/news/scottish-medicines-consortium-accepts-iluvien-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis/2478259/The Scottish Medicines Consortium (SMC) has accepted Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS) in adults.1<
- Zeiss Launches “Vision in County” Cataract Development Program in Shandong, Chinahttps://modernod.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/The “Vision in County” Cataract Development Program by Zeiss was officially launched in Shandong, China on September 3, 2020. At the event, the first training base was established in the Affiliated Eye Hospital of
- Quantel Medical Launches Mosar High-Definition Imaging System for for Easyrethttps://modernod.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/Quantel Medical announced the launch of Mosar, a high-definition imaging system, on its yellow laser Easyret. Mosar features an HD camera, a screen and computer, and enhances the retinal laser treatment procedu
- Nearly One Quarter of Chinese Children Hospitalized With COVID-19 Developed Eye Symptomshttps://modernod.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/Among Chinese children hospitalized for COVID-19, nearly a quarter developed ocular symptoms, a new study finds, Reuters reported. Most children developed eye symptoms later in the disease, but in nine, ocular manifestations were the first
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was
- HHS Bids $250 Million Contract Meant to ‘Defeat Despair and Inspire Hope’ on Coronavirushttps://modernod.com/news/hhs-bids-250-million-contract-meant-to-defeat-despair-and-inspire-hope-on-coronavirus/2478236/As the presidential election fast approaches, the Department of Health and Human Services is bidding out a more than $250 million contract to a communications firm as it seeks to “defeat despair and inspire hope” about the coronavirus pandemic, according to a
- Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/Nicox SA announced that it completed enrollment of the adaptive design patient cohort in its multicenter Mont Blanc phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution 0.005% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t
- AEYE Health Develops Advanced AI-Based Retinal Screening With Instant Resultshttps://modernod.com/news/aeye-health-develops-advanced-ai-based-retinal-screening-with-instant-results/2478232/AEYE Health has developed an AI-based retinal screening system that provides analysis and diagnostic results within 60 seconds. AEYE Health’s advanced machine learning and artificial intelligence technologies offer instant and accurate screening and analysis of the retina for the det